HeyJaredGOG GYN-LIVE - INDUSTRY SUPPORTED SYMPOSIA
The GOG Foundation, Inc. and GOG Partners are thrilled to share enduring education from Industry Supported Symposia that showcases clinical trials and other newsworthy education, from major medical meetings throughout the year.
- Indexed episodes, last 90 days
- 5
- Latest publication
- Aug 13, 2026
- Audience
- Checking…
- Earliest in this view
- Aug 13, 2026
Latest episodes
Future of ADCs: Accelerating Progress in Ovarian and Endometrial Cancer (opens the original)
Read excerpt
The GOG Foundation, Inc. and GOG Partners welcomes gynecologic oncologists, oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with gynecologic malignancies to access the Future of ADCs: Accelerating Progress in Ovarian and Endometrial Cancer Enduring Educational Symposium that was presented at the FSGO 2026 Annual Meeting in Long Boat Key, Florida a on Sunday, June 14, 2026. This educational activity is supported by an independent medical education grant
The GOG Highlight Reel – July 2026 (opens the original)
Read excerpt
The GOG Highlight Reel distills practice-changing information disclosed during recent major medical meetings into a two-and-a-half-hour segment. This comprehensive course examines recent clinical trial data in gynecologic malignancies, offering insights on data presentations, ongoing research, and drug approvals shaping the field. It addresses common gynecologic malignancies, aiding physicians in comprehending the evolving treatment landscape, including understanding trials in progress. Particip
Evolving Evidence and Treatment Strategies in Low Grade Serous Ovarian Cancer (LGSOC) (opens the original)
Read excerpt
This program provides an in‑depth review of the evolving treatment landscape in ovarian cancer with a focus on emerging science and practical application in patient care. Participants will explore the current competitive landscape, new indications, and recent data surrounding folate receptor alpha–targeted therapies. The session will also look ahead to future developments, including the role of antibody–drug conjugates (ADCs) in low‑grade serous ovarian cancer, MEK inhibitors, and the significan
ctDNA-based MRD testing and monitoring in gynecologic cancers (opens the original)
Read excerpt
Molecular residual disease (MRD) tracking via tumor-informed circulating tumor DNA (ctDNA) is redefining the surveillance and management paradigm in gynecologic oncology. This session delivers a data-driven evaluation of the evolving role of ctDNA in identifying subclinical recurrence and quantifying real-time treatment response across ovarian, uterine, and cervical cancers—frequently months ahead of traditional biomarkers and diagnostic imaging. Participants will examine the mechanistic basis o
Precision Decision Making in Platinum Resistant Ovarian Cancer: Folate Receptor Alpha Expression and Other Biomarkers Into Contemporary Care (opens the original)
Read excerpt
Despite advances in ovarian cancer treatment, outcomes for patients with platinum‑resistant disease remains poor, with therapeutic decisions becoming increasingly complex as novel biomarkers and targeted therapies emerge. This 45‑minute case‑based educational program will provide clinicians with practical guidance on integrating folate receptor alpha (FRα) testing into real‑world decision‑making, alongside emerging considerations such as weekly paclitaxel and/or bevacizumab eligibility, PD-L1, H
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
No verified audience measurement yet.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.
See coverage about GOG GYN-LIVE - INDUSTRY SUPPORTED SYMPOSIA